Research Overview
· Last Reviewed May 2, 2026· PSI Editorial Board· IndependentCan Peptides Boost My Immune System?
The honest picture across 8 immune scenarios: what's been studied, what's confirmed in humans, and where validated treatments still rule.
WHAT ARE YOU INVESTIGATING?
Domain
Animal Studies
Human Trials
Chronic hepatitis B
thymosin alpha-1 abroad indication
Cancer adjuvant immune support
alongside chemotherapy
Post-acute viral recovery
post-COVID, post-flu
Immunosenescence
aging immune decline
Recurrent infection
primary or secondary immunodeficiency
Mucosal immune defense
barrier-level protection
Vaccine response augmentation
adjuvant role
Sepsis adjunct
ICU contexts
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Immune support is the indication where peptide research has its most clinically validated representative. That representative is thymosin alpha-1. The compound is FDA-approved in over 35 countries for chronic hepatitis B. International use also extends to cancer adjuvant settings. It is NOT FDA-approved in the United States. The international clinical safety database spans decades.
LL-37 is the body's own antimicrobial peptide. It plays a documented role in innate immune defense at mucosal surfaces and during wound healing. Therapeutic LL-37 administration has not been tested in adequately powered controlled human trials. KPV is an alpha-MSH-derived anti-inflammatory tripeptide with animal model evidence. BPC-157 has tissue-repair anti-inflammatory effects. It cannot currently be legally compounded by US 503A pharmacies. Thymalin is a Russian-origin immunomodulator with limited Western controlled trial validation.
None of these peptides is FDA-approved in the United States for any immune indication. The validated treatments for immune dysfunction are vaccines, immunoglobulin replacement therapy (IVIG, SCIG), hematopoietic growth factors (filgrastim/Neupogen, sargramostim/Leukine), and antiviral drugs. Peptide adjunct use should layer alongside, not replace, validated treatment under physician supervision. For current regulatory status, see the FDA Status Tracker. This page maps what's studied versus what marketing claims, by immune scenario.
Peptides vs vaccines and immunoglobulin therapy
Where research-grade peptides stand against the validated immune therapies
Vaccines are the gold standard intervention for adaptive immunity. Decades of trial evidence support vaccine efficacy across infectious disease prevention. Childhood vaccination programs have eliminated or controlled measles, polio, diphtheria, tetanus, pertussis, hepatitis B, and many other diseases. Adult vaccination supports influenza, pneumococcal disease, shingles, COVID-19, and HPV-related cancer prevention. Effect sizes for vaccine-preventable disease prevention are substantial and well-characterized.
Immunoglobulin replacement therapy (IVIG, intravenous immunoglobulin; SCIG, subcutaneous immunoglobulin) is FDA-approved for primary immunodeficiency disorders, certain autoimmune conditions, and selected infectious complications. The therapy provides passive transfer of antibodies pooled from thousands of donors. Multiple Phase 3 trials support efficacy across primary immunodeficiency, idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy.
Hematopoietic growth factors include filgrastim (Neupogen, granulocyte colony-stimulating factor) and sargramostim (Leukine, granulocyte-macrophage colony-stimulating factor). They are FDA-approved for chemotherapy-induced neutropenia and other contexts of low white blood cell count. The compounds restore neutrophil counts and reduce infection risk. They are protein therapeutics, not the small peptides on this page.
Peptide evidence for general immune support is much thinner. Thymosin alpha-1 has FDA approval abroad for chronic hepatitis B and is used internationally as cancer adjuvant. It does not match the trial-evidence depth of vaccines for preventing infectious disease, IVIG for primary immunodeficiency, or hematopoietic growth factors for neutropenia. LL-37, KPV, BPC-157, and thymalin have no FDA approval for any immune indication.
PSI's reading: for confirmed immune dysfunction, vaccines, IVIG, and hematopoietic growth factors are validated standards under specialist guidance. They have decades of trial evidence and clear effect sizes. Peptides may have a research-adjunct role in specific contexts, particularly thymosin alpha-1 in hepatitis or cancer adjuvant settings. They are not equivalent alternatives. Anyone framing peptides as primary immune therapy in 2026 is reading further into the data than the data supports.
Peptides vs lifestyle and validated nutrition for general immune support
Foundational interventions vs research-grade peptides
For healthy adults seeking general immune support, the validated interventions are foundational. Adequate sleep (7 to 9 hours nightly) is associated with better vaccine response and lower infection risk. Regular physical activity supports immune function across multiple measures. Balanced nutrition with adequate protein, micronutrients, and fiber supports immune cell function. Smoking cessation, moderate alcohol consumption, and stress management add further effects.
Specific micronutrient interventions have evidence in deficiency contexts. Vitamin D supplementation may reduce respiratory infection risk in deficient individuals. Zinc may reduce the duration of common cold symptoms. Vitamin C has limited but consistent evidence for cold prevention in physically stressed populations. None of these is a peptide. The evidence base is much larger for foundational lifestyle and nutrition than for peptides.
Peptide evidence for general immune support in healthy adults is preliminary. Thymosin alpha-1 has international approval for chronic hepatitis B, not for general immune enhancement. KPV, LL-37, BPC-157, and thymalin have no controlled human trials in healthy adult immune support contexts. The mechanism rationales are reasonable. The evidence is animal-grade or limited to specific clinical populations.
PSI's reading: for healthy adults seeking general immune support, the dominant interventions with the strongest evidence are sleep, exercise, balanced nutrition, and smoking cessation. Peptides may add small effects in specific clinical populations or for specific viral indications. They will not substitute for foundational lifestyle factors. Anyone considering peptides for general immune enhancement should optimize lifestyle first.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Across the 5 most-discussed peptides for immune support, PSI catalogs the published animal studies and human trials below. None of these compounds has FDA approval for immune support.
Thymosin Alpha-1
Deepest international clinical evidence on this page. FDA-approved in 35+ countries for chronic hepatitis B. International cancer adjuvant use. Not US-approved.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
Chronic hepatitis B FDA-approved indication abroad | 8 Strong antiviral and immunomodulation data in animal HBV models. | 8 Multiple controlled trials supported FDA approval in 35+ countries for chronic hepatitis B. Not US-approved. |
Cancer adjuvant immune support alongside chemotherapy | 6 Improved immune response and tumor outcome markers in animal cancer models. | 4 International clinical use as adjuvant in melanoma, hepatocellular carcinoma, and other cancers. Not US-approved for cancer indications. |
Sepsis adjunct ICU contexts | 5 Improved survival and reduced inflammatory markers in animal sepsis models. | 2 Limited human exploration in sepsis adjunct contexts. Not FDA-approved for sepsis. |
Vaccine response augmentation adjuvant role | 4 Enhanced vaccine response reported in animal immunization models. | 2 Limited international use as vaccine adjuvant in elderly populations. |
Post-transplant immune support non-defense primary use | 4 Improved immune reconstitution in animal transplant models. | 2 Limited human exploratory data. Not FDA-approved for transplant indications. |
LL-37
Body's own antimicrobial peptide. Documented endogenous role in innate immunity and wound healing. No interventional human therapeutic trials.
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
Antimicrobial defense (bacteria) broad-spectrum activity | 12 Direct antimicrobial activity demonstrated against multiple bacterial pathogens in animal infection models. | 0 No interventional trials of exogenous LL-37 as antibacterial therapy. |
Antiviral defense respiratory and other viruses | 6 Antiviral activity reported against influenza, respiratory syncytial virus, and others in animal models. | 0 No interventional trials of exogenous LL-37 as antiviral therapy. |
Wound healing (general) broader immune-tissue interface | 6 Faster wound closure and improved tissue regeneration reported across animal models. | 1 Observational study reported deficient LL-37 expression in chronic non-healing wounds; correlative, not interventional. |
Mucosal immunity barrier-level defense | 5 Endogenous LL-37 supports mucosal antimicrobial defense in animal models. | 0 No interventional trials of exogenous LL-37 for mucosal immune enhancement. |
KPV
Alpha-MSH-derived anti-inflammatory tripeptide. Solid mouse colitis and broader inflammation animal models. No controlled human trials.
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
Inflammatory bowel disease colitis animal models | 5 Reduced colitis severity and lower pro-inflammatory cytokines reported across animal models. | 0 None published. |
General immune modulation broader cytokine balance | 8 Anti-inflammatory effects across multiple inflammation models, with implications for immune balance. | 0 None published. |
Immune cell function dendritic cell, T-cell, macrophage | 4 Modulated immune cell function in animal models through melanocortin receptor pathways. | 0 None published. |
BPC-157
Tissue-repair compound with anti-inflammatory effects in animal models. Cannot currently be legally compounded by US 503A pharmacies. WADA prohibited.
WADA Section S2 prohibition. BPC-157 is prohibited under the World Anti-Doping Agency code. Athletes subject to drug testing should not use this compound.
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
Anti-inflammatory immune effects broader immune modulation | 7 Reduced inflammatory cytokines and improved tissue-repair markers reported across animal models. | 0 None published for immune indications. |
Tissue-repair during immune challenge infection or injury contexts | 5 Tissue-protective effects reported in animal injury and infection models. | 0 None published. |
Thymalin
Russian-origin polypeptide-complex immunomodulator from the Khavinson group. Russian clinical literature. Limited Western controlled trial validation.
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
Immunosenescence aging-related immune decline | 6 Improved immune markers in aged animal models reported by Khavinson group. | 3 Russian clinical literature reports use in elderly populations. Western controlled trial documentation is limited. |
Viral infection support immunomodulation context | 4 Antiviral immune support reported in animal models. | 2 Russian clinical use reported. Western controlled trial documentation is limited. |
Autoimmune inflammation broader autoimmunity | 3 Limited animal data for autoimmune inflammation specifically. | 0 No published Western controlled trials. |
What's Marketed vs What's Studied
6 common claims, corrected.
“Thymosin alpha-1 is FDA-approved for immune support.”
Thymosin alpha-1 is FDA-approved abroad in 35+ countries for chronic hepatitis B and as cancer adjuvant. It is NOT US-approved. The international approval is not for general immune enhancement in healthy adults.
“Peptides replace vaccines for adaptive immunity.”
Vaccines have decades of trial evidence for infectious disease prevention. No peptide has matched this evidence base. Peptides like thymosin alpha-1 may augment vaccine response in specific populations but do not replace vaccines.
“LL-37 supplementation enhances immune function.”
LL-37 is the body's own antimicrobial peptide. Endogenous role is documented. Therapeutic exogenous administration has not been tested interventionally. Some animal studies show pro-inflammatory effects that complicate clinical use.
“KPV strengthens the immune system.”
KPV has animal model anti-inflammatory immune effects through melanocortin receptors. No controlled human trials exist for any immune indication.
“BPC-157 boosts immunity.”
BPC-157 has tissue-repair anti-inflammatory effects in animal models. Direct interventional immune trials are absent. The compound cannot currently be legally compounded by US 503A pharmacies.
“Thymalin reverses immunosenescence.”
Thymalin has Russian clinical literature reporting immune effects in elderly populations. Western multicenter controlled trial validation is limited. The compound is not FDA-approved in the United States or most Western countries.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get a clear immune condition diagnosis first.
Immunodeficiency, chronic viral infection, autoimmune disease, post-cancer immune compromise, and immunosenescence are different conditions with different treatment ladders. An immunologist, hepatologist, oncologist, or appropriate specialist with proper workup is the right starting point. Self-diagnosis followed by peptide self-treatment is not evidence-based care.
Optimize validated approaches first.
Vaccines for prevention. Lifestyle factors (sleep, exercise, nutrition, smoking cessation) for general immune health. Validated treatments for diagnosed conditions. Beginning treatment with research peptides instead of these standards is not appropriate.
Work with a specialist who knows both validated standards and peptide research.
Avoid clinics whose primary business is selling peptides. A qualified immunologist, hepatologist, or oncologist can frame peptides accurately as research-grade adjuncts. The right physician prioritizes disease control through evidence-based therapy first.
Compounded peptides require physician prescription and licensed pharmacy.
503A pharmacies prepare patient-specific compounds; 503B outsourcing facilities prepare office-use stock. BPC-157 cannot currently be legally compounded by US 503A pharmacies due to its 2023 Category 2 placement. Demand third-party HPLC purity testing and certificates of analysis on each batch where applicable.
Track objective markers, not just symptoms.
Immunoglobulin levels, lymphocyte subsets, viral load, vaccine antibody titers, and infection frequency are objective measures. Symptomatic improvement on peptides without objective marker improvement is not evidence of immune effect. Peptide adjunct effects should be measured the same way validated treatments are measured.
Watching and waiting alongside validated treatment is a legitimate option.
BPC-157 cannot currently be legally compounded in the US. KPV, LL-37, and thymalin lack controlled human immune trials. Stronger human evidence may come from ongoing research over years. There is no penalty for being patient with peptide adoption while optimizing validated immune treatment.
The regulatory landscape for immune-support peptides is dynamic. Thymosin alpha-1 remains FDA-approved abroad for chronic hepatitis B and cancer adjuvant but not in the US for any indication. BPC-157's 2023 Category 2 placement on the 503A bulks list blocks legal compounding by US 503A pharmacies pending additional safety data. The Outsourcing Facilities Association is actively litigating FDA compounding decisions in the Northern District of Texas. Court rulings, new safety submissions, or legislative action could shift availability of multiple compounds. KPV, LL-37, and thymalin have no FDA approval pathways currently in progress. The vaccine and biologic landscape continues to expand with new approvals. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Do peptides actually boost the immune system?
Most immune-support peptides work through reasonable mechanism rationales. Thymosin alpha-1 modulates T-cell and dendritic cell function. LL-37 has direct antimicrobial activity and innate immune signaling. KPV activates melanocortin receptors with anti-inflammatory effects. BPC-157 has tissue-repair anti-inflammatory mechanisms. Thymalin acts through bioregulator peptide pathways. The translation to controlled human immune trials has not happened for most peptides on this page. Thymosin alpha-1 has the strongest international evidence through FDA approval abroad for chronic hepatitis B. The validated treatments for immune dysfunction are vaccines, IVIG, hematopoietic growth factors, and antiviral drugs. Anyone framing peptides as primary immune therapy is overstating the evidence.
Is thymosin alpha-1 FDA-approved?
Thymosin alpha-1 is FDA-approved in over 35 countries for chronic hepatitis B and as an immune adjuvant in cancer treatment contexts. It is NOT FDA-approved in the United States for any indication. The compound is sold internationally as Zadaxin by SciClone Pharmaceuticals. The international approval covers chronic HBV and cancer adjuvant settings. It does not extend to general immune enhancement in healthy adults. Off-label use exists in compounded formulations under physician prescription. Adequately powered US-grade controlled trials in healthy adult immune support have not been completed.
What is LL-37 and why does it matter for immunity?
LL-37 is the body's own antimicrobial peptide. Neutrophils, epithelial cells, and other immune cells make it naturally as part of innate immune defense. The compound has direct antimicrobial activity against bacteria, viruses, and fungi. It also recruits immune cells to infection sites. Heilborn and colleagues (Journal of Investigative Dermatology 2003, PMID 12787106) established LL-37's role in human wound repair. Deficient LL-37 expression has been associated with chronic non-healing wounds and recurrent infection in some populations. Therapeutic exogenous LL-37 administration has not been tested in adequately powered controlled human trials. The compound is research-only with no FDA approval.
Can KPV strengthen the immune system?
KPV is a tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). The compound carries the parent molecule's anti-inflammatory activity through melanocortin receptors. Animal models report reduced inflammation in IBD and broader inflammation contexts. Singh and colleagues (Inflammatory Bowel Diseases 2014, PMID 25358065) demonstrated effects in DSS-induced mouse colitis. The clinical evidence is preclinical. KPV has not undergone published controlled human trials for any immune indication. The compound is research-only with no FDA approval.
Does BPC-157 help the immune system?
BPC-157 has anti-inflammatory and immune-relevant effects observed alongside tissue-repair signaling in animal models. The mechanism for immune relevance is indirect through anti-inflammatory cytokine modulation. Direct interventional studies in immune dysfunction or immunodeficiency are absent. Three small uncontrolled BPC-157 human studies (knee pain, interstitial cystitis, IV safety) total fewer than 30 patients. None addresses immune indications. In 2023, FDA placed BPC-157 in Category 2 of the 503A bulks list. The compound cannot be legally compounded by US pharmacies. WADA prohibits BPC-157 in competitive athletes under Section S2.
What is thymalin? How does it differ from thymosin alpha-1?
Thymalin is a polypeptide complex extracted from calf thymus. It is different from thymosin alpha-1, which is a specific 28-amino-acid peptide. The Khavinson research group in Russia has been the primary developer of thymalin over decades. Russian clinical literature reports use across viral infection, immunosenescence, and aging-related immune decline. Western controlled trial validation is limited. Language barriers and absence of multicenter Western RCTs constrain Western evidence synthesis. Thymalin is not FDA-approved in the United States or most Western countries. PSI's reading: thymalin sits at the periphery of evidence-graded peptide research compared to thymosin alpha-1.
How do peptides compare to vaccines for immunity?
Vaccines are the gold standard intervention for adaptive immunity. Decades of trial evidence support vaccine efficacy across infectious disease prevention. Childhood vaccination programs have controlled measles, polio, diphtheria, tetanus, pertussis, hepatitis B, and many other diseases. Adult vaccination supports influenza, pneumococcal disease, shingles, COVID-19, and HPV-related cancer prevention. No peptide has matched vaccine evidence for infectious disease prevention. Thymosin alpha-1 is sometimes used internationally as a vaccine adjuvant in elderly populations, but this is not a replacement for the underlying vaccine. Patients should not substitute peptides for vaccines.
How do peptides compare to IVIG for immunodeficiency?
Immunoglobulin replacement therapy (IVIG, intravenous; SCIG, subcutaneous) is FDA-approved for primary immunodeficiency disorders, certain autoimmune conditions, and selected infectious complications. The therapy provides passive transfer of antibodies pooled from thousands of donors. Multiple Phase 3 trials support efficacy. Peptides are not equivalent alternatives to IVIG for primary immunodeficiency. They are research-grade biology with much thinner clinical evidence. Substituting peptides for IVIG in confirmed immunodeficiency risks serious infection. Patients with primary or secondary immunodeficiency should work with immunology on validated treatment.
Can peptides help with chronic hepatitis B or hepatitis C?
Thymosin alpha-1 is the peptide with the most direct overlap to chronic viral hepatitis. The compound is FDA-approved abroad in 35+ countries for chronic hepatitis B based on multiple controlled trials. International clinical use also includes chronic hepatitis C adjunctive therapy. The mechanism is immunomodulatory rather than direct-acting antiviral. For chronic hepatitis B, modern direct-acting antivirals like tenofovir and entecavir are typically first-line in international guidelines. For chronic hepatitis C, direct-acting antiviral combinations like sofosbuvir/velpatasvir cure most patients in 8 to 12 weeks. Thymosin alpha-1 may be considered as adjunct or alternative in specific patient subsets. Patients should work with hepatology on validated antiviral therapy.
Are these peptides legal in the US?
Regulatory status varies by compound. Thymosin alpha-1 is not US FDA-approved but is sold abroad as Zadaxin. KPV, LL-37, and thymalin are not FDA-approved and are research compounds. BPC-157 is in Category 2 of the FDA's 503A bulks list as of 2023, blocking legal compounding by US 503A pharmacies. Compounded peptide formulations for human use require physician prescription and a state-licensed compounding pharmacy where applicable. WADA prohibits BPC-157 under Section S2. KPV, LL-37, thymosin alpha-1, and thymalin are not WADA-prohibited. Regulatory status is dynamic. Research-chemical sale exists for most compounds but does not constitute legal medical use.
Can I use peptides during cancer treatment?
Thymosin alpha-1 is used internationally as a cancer adjuvant alongside chemotherapy and immunotherapy. International clinical literature supports use in melanoma, hepatocellular carcinoma, and other cancers. The compound is not US FDA-approved for cancer indications. Anyone with cancer considering peptide adjunct therapy should work with their oncologist on the specifics. Peptide adjunct use during cancer treatment requires careful consideration of drug interactions, immune modulation timing, and treatment goals. Peptides should not replace evidence-based cancer therapy. The clinical decision belongs to the oncology team familiar with the patient's specific cancer, treatment regimen, and goals.
What about peptides for post-COVID or post-acute viral recovery?
Post-acute viral recovery is an emerging clinical area. Long COVID and post-acute infection syndromes have garnered substantial research attention since 2020. Validated treatments are limited and largely supportive. Some clinicians have explored thymosin alpha-1 and other immunomodulatory peptides in post-COVID contexts. Adequately powered controlled trials specific to post-COVID or post-acute viral recovery are limited. Anyone considering peptides for post-acute viral recovery should work with a physician familiar with the evolving evidence base. Treatment for post-acute viral syndromes should integrate with broader rehabilitation, sleep optimization, graded exercise where tolerated, and management of specific symptom clusters.
How do peptides compare to lifestyle interventions for general immunity?
For healthy adults seeking general immune support, the validated interventions are foundational. Adequate sleep (7 to 9 hours nightly) supports immune function and vaccine response. Regular physical activity supports immune measures across multiple studies. Balanced nutrition with adequate protein, micronutrients, and fiber supports immune cell function. Smoking cessation, moderate alcohol consumption, and stress management add further effects. Peptide evidence for general immune support in healthy adults is preliminary. Lifestyle and nutrition produce documented effects today. Peptides will not substitute for foundational lifestyle factors. Anyone considering peptides for general immune enhancement should optimize lifestyle first.
Are there side effects to immune-support peptides?
Side-effect profiles vary by compound. Thymosin alpha-1 is generally well-tolerated based on the international hepatitis B safety database. Common effects include injection-site reactions, mild fatigue, and transient flu-like symptoms. KPV is generally well-tolerated in animal studies; controlled human safety data is limited. LL-37 administration has potential for pro-inflammatory effects given its mixed-direction biology. Interventional human safety data is essentially absent. BPC-157 has limited human safety data. The 2023 FDA Category 2 placement reflects insufficient safety data and concerns about immunogenicity and impurities. Thymalin Western safety data is limited. Long-term safety for peptide use specifically in chronic immune support is unknown for most compounds.
What questions should I ask a doctor about peptides for immune support?
Ask: (1) Do I have a diagnosed immune condition (immunodeficiency, chronic viral infection, autoimmunity, post-cancer immune compromise)? Treatment depends on the diagnosis. (2) Have I optimized validated approaches (vaccines, lifestyle, nutrition, treatment of underlying conditions) before considering peptides? (3) What evidence level supports the peptide being considered for my specific context? Animal data, PK data, or interventional human data. (4) Is the peptide being recommended as an adjunct to validated treatment, or as a replacement? Replacement is not evidence-supported. (5) What objective markers (immunoglobulin levels, lymphocyte subsets, viral load, infection frequency) will track effect? (6) Are the formulations being prescribed from a state-licensed compounding pharmacy with third-party analytical testing?
Can peptides help with autoimmune disease and immune dysregulation?
Autoimmune disease involves dysregulated immune attack on self tissues. The validated treatments are biologics (anti-TNF, anti-IL-17, anti-IL-23, anti-IL-6, anti-CD20), JAK inhibitors, DMARDs (methotrexate, hydroxychloroquine), corticosteroids, and immunosuppressants. None is a peptide on this page. Peptide research for autoimmune dysregulation is preliminary. Thymosin alpha-1 has theoretical immunomodulatory effects relevant to autoimmunity. KPV has animal anti-inflammatory data. Controlled human autoimmune trials for peptides on this page are absent. Patients with diagnosed autoimmune disease should work with rheumatology, gastroenterology, dermatology, or appropriate specialty on validated treatment. See the [PSI inflammation condition page](/conditions/peptides-for-inflammation) for detailed coverage of peptide research in autoimmune contexts.
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.